Univariate analysis
| End point/variable . | P value . |
|---|---|
| Freedom from second failure | |
| Age (3 groups) | .006 |
| Gender | .084 |
| B symptoms at progression | .084 |
| Karnofsky performance score at progression (4 groups) | .0004 |
| Primary stage (intermediate vs advanced) | .15 |
| Stage at progression (I/II vs III/IV) | .1 |
| Localization of progressive disease | .015 |
| Temporary remission on first-line treatment | .0009 |
| Time of occurrence of progression | .19 |
| Overall survival | |
| Age (3 groups) | <.0001 |
| Gender | .48 |
| B symptoms at progression | .0001 |
| Karnofsky performance score at progression (4 groups) | <.0001 |
| Primary stage (intermediate vs advanced) | .23 |
| Stage at progression (I/II vs III/IV) | .0025 |
| Localization of progressive disease | .015 |
| Temporary remission on first-line treatment | .0009 |
| Time of occurrence of progression | .1 |
| End point/variable . | P value . |
|---|---|
| Freedom from second failure | |
| Age (3 groups) | .006 |
| Gender | .084 |
| B symptoms at progression | .084 |
| Karnofsky performance score at progression (4 groups) | .0004 |
| Primary stage (intermediate vs advanced) | .15 |
| Stage at progression (I/II vs III/IV) | .1 |
| Localization of progressive disease | .015 |
| Temporary remission on first-line treatment | .0009 |
| Time of occurrence of progression | .19 |
| Overall survival | |
| Age (3 groups) | <.0001 |
| Gender | .48 |
| B symptoms at progression | .0001 |
| Karnofsky performance score at progression (4 groups) | <.0001 |
| Primary stage (intermediate vs advanced) | .23 |
| Stage at progression (I/II vs III/IV) | .0025 |
| Localization of progressive disease | .015 |
| Temporary remission on first-line treatment | .0009 |
| Time of occurrence of progression | .1 |